FDA Strips Health Risk Warnings from Menopause Hormone Therapy
FDA will remove black box warnings from menopause hormone replacement therapies, reversing earlier warnings and potentially increasing accessibility while prompting caution about overstated benefits.
Women With Perinatal Depression Could Soon Face a Big Hurdle
Adding a black-box warning for SSRIs in pregnancy is contested due to fetal risk concerns versus potential harm from deterring necessary maternal treatment.